Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 9/20 | 0.39 |
| ▸ | F2 | P00734 | 3/20 | 0.39 |
| ▸ | PLAU | P00749 | 3/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | MARK3 | P27448 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8216089 | 0.84 | ELANE (0.52) | MAP2K4CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL11754694 | 0.83 | ELANE (0.48) | L3MBTL1PDGFRACDK5TYRO3ELANE | |
| SCHEMBL660243 | 0.83 | MAP2K4 (0.45) | MAP2K4PDGFRACDK5TYRO3SMARCA2 | |
| SCHEMBL29626660 | 0.82 | MAP2K4 (0.44) | MAP2K4CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL7016168 | 0.82 | L3MBTL1 (0.44) | MAP2K4CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL30438051 | 0.82 | MAP2K4 (0.47) | MAP2K4CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2674135 | 0.82 | MAP2K4 (0.44) | MAP2K4CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL155708 | 0.82 | MAP2K4 (0.44) | MAP2K4CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL28157040 | 0.82 | MAP2K4 (0.44) | MAP2K4CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL13737806 | 0.82 | PDGFRA (0.47) | MAP2K4PDGFRACDK5TYRO3SMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4471029-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER | Suzhou Genhouse Bio Co., Ltd. (CN) | 2024-12-04 | — | — | EP | disclosed |
| US-20240391923-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER | SUZHOU GENHOUSE BIO CO., LTD. (CN) | 2024-11-28 | — | — | US | disclosed |
| CN-118541371-A | Methionine adenosyltransferase 2A inhibitors for the treatment of MTAP deleted cancers | 勤浩医药（苏州）有限公司 | 2024-08-23 | — | — | CN | disclosed |
| WO-2023143356-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER | 勤浩医药（苏州）有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4108663-A1 | SUBSTITUTED ARYL COMPOUND | Simcere Pharmaceutical Co., Ltd. (CN) | 2022-12-28 | — | — | EP | disclosed |
| CN-115315423-A | Substituted aryl compounds | 先声药业有限公司 | 2022-11-08 | — | — | CN | disclosed |
| US-20160362408-A1 | ARYL- AND HETARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-15 | — | — | US | disclosed |
| US-20160362408-A1 | ARYL- AND HETARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-15 | — | — | US | disclosed |
| US-20160362408-A1 | ARYL- AND HETARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-15 | — | — | US | disclosed |
| EP-3077394-A1 | ARYL- AND HETARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015082411-A1 | ARYL- AND HETARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015082411-A1 | ARYL- AND HETARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-11 | — | — | WO | disclosed |
| WO-2006135383-A2 | INDAZOLES | MYRIAD GENETICS, INC. (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362408-A1 | ARYL- AND HETARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | AADAC, PAH, CYP2C8 | MAP2K4 2537/4885CHRM2 2264/4885CHRM4 1954/4885 |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | RAD51, FANCI, BLM | MAP2K4 3512/4885CHRM2 4681/4885CHRM4 4740/4885 |
| US-20240391923-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER | MAT2B, MAT2A, MAT1A | MAP2K4 3436/4885CHRM2 4427/4885CHRM4 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.